The Biochemical Prognostic Factors of Subclinical Hypothyroidism

Article information

Endocrinol Metab. 2014;29(2):144-145

Publication date (electronic) : 2014 June 26

doi : https://doi.org/10.3803/EnM.2014.29.2.144

Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.

Corresponding author: You Jin Lee. Center for Thyroid Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea. Tel: +82-31-920-1664, Fax: +82-31-920-0846, euleemd@gmail.com

Subclinical hypothyroidism (SCH) is a very common condition and is defined as elevated serum thyroid-stimulating hormone (TSH) level with normal levels of circulating free thyroxine and triiodothyronine [1]. Recent population-based Korean studies have reported a high prevalence of 11% to 17% [2]. SCH is more common in women (6% to 10%) than in men (2% to 4%) [3,4,5]. Age is also a well-known risk factor. Some large studies showed significant positive correlation between age and SCH prevalence [6]. Serum thyroid peroxidase antibody (TPO Ab) positivity is associated with the prevalence of SCH [3,4,7].

In the Whickham 20-year follow-up study, risk of developing overt hypothyroidism was significantly higher in subjects with positive TPO Ab and increased TSH level than in those with only elevated TSH level [8]. In addition, iodine intake [9], racial differences [4], cigarette smoking [10], and cold environmental temperature [11] have also been suggested as risk factors of SCH.

There have been some controversies about effects of SCH on obesity, dyslipidemia, cardiovascular disease, and cognition [12,13,14,15,16,17]. Some studies showed increased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in SCH subjects [6], while other studies showed no differences in lipid profile between SCH and euthyroid subjects [4]. A randomized double-blind placebo-controlled trial, 12-month levothyroxine treatment with 31 patients resulted in significant reductions in TC and LDL-C levels compared with those of 32 placebo subjects [17].

Therefore, the treatment of SCH is controversial. Prediction of progression of overt hypothyroidism is very important in a clinical setting. However, there are no definite predicting factors. In the study of Lee et al. [18], the authors compared characteristics of SCH patients according to initial TSH level and spontaneous improvement and identified predicting factors of progression to overt hypothyroidism. Higher initial TSH level and TPO-Ab positivity or titers were significantly correlated with maintenance of SCH and unfavorable lipid profiles. Initial TSH level was an independent and strong prognostic factor even in SCH subjects with mildly elevated TSH (5 to 10 mU/L). Although more studies are needed, initial TSH level and TPO Ab titer are very useful predicting factors when deciding on treatment for SCH.

Notes

No potential conflict of interest relevant to this article was reported.

References

1. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012;18:988–1028. 23246686.

2. Choi HS, Park YJ, Kim HK, Choi SH, Lim S, Park DJ, Jang HC, Cho NH, Cho BY. Prevalence of subclinical hypothyroidism in two population based-cohort: Ansung and KLoSHA cohort in Korea. J Korean Thyroid Assoc 2010;3:32–40.

3. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y, Wang W, Gao T, Li C. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006;354:2783–2793. 16807415.

4. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–499. 11836274.

5. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med 1985;145:1386–1388. 4026469.

6. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526–534. 10695693.

7. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977;7:481–493. 598014.

8. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55–68. 7641412.

9. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991;34:77–83. 2004476.

10. Cho NH, Choi HS, Kim KW, Kim HL, Lee SY, Choi SH, Lim S, Park YJ, Park do J, Jang HC, Cho BY. Interaction between cigarette smoking and iodine intake and their impact on thyroid function. Clin Endocrinol (Oxf) 2010;73:264–270. 20105185.

11. Kim TH, Kim KW, Ahn HY, Choi HS, Won H, Choi Y, Cho SW, Moon JH, Yi KH, Park do J, Park KS, Jang HC, Kim SY, Park YJ. Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status. J Clin Endocrinol Metab 2013;98:3420–3429. 23771919.

12. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008;125:41–48. 17434631.

13. Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. J Intern Med 2006;260:53–61. 16789979.

14. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005;165:2467–2472. 16314542.

15. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jorgensen T. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019–4024. 15870128.

16. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270–278. 10681281.

17. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860–4866. 11600554.

18. Lee MW, Shin DY, Kim KJ, Hwang S, Lee EJ. The biochemical prognostic factors of subclinical hypothyroidism. Endocrinol Metab 2014;29:154–162.

Article information Continued

(open-access, http://creativecommons.org/licenses/by-nc/3.0/) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.